Spark Therapeutics Inc (NASDAQ:ONCE) CFO Stephen W. Webster sold 10,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $70.14, for a total transaction of $701,400.00. Following the sale, the chief financial officer now owns 12,500 shares in the company, valued at approximately $876,750. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
Spark Therapeutics Inc (NASDAQ ONCE) traded down $1.26 during mid-day trading on Wednesday, hitting $69.71. 455,512 shares of the company’s stock were exchanged, compared to its average volume of 397,122. Spark Therapeutics Inc has a 12-month low of $47.03 and a 12-month high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). The company had revenue of $1.90 million for the quarter, compared to the consensus estimate of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.07) EPS. equities research analysts expect that Spark Therapeutics Inc will post -7.6 EPS for the current fiscal year.
ONCE has been the topic of several research reports. Chardan Capital upgraded shares of Spark Therapeutics from a “neutral” rating to a “buy” rating and raised their price objective for the company from $60.00 to $100.00 in a research report on Tuesday, August 8th. Evercore ISI initiated coverage on shares of Spark Therapeutics in a research report on Wednesday, August 16th. They set an “in-line” rating and a $83.00 price objective on the stock. Cantor Fitzgerald restated a “buy” rating on shares of Spark Therapeutics in a research report on Friday, August 25th. BidaskClub upgraded shares of Spark Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, August 26th. Finally, Barclays started coverage on shares of Spark Therapeutics in a research report on Wednesday, September 6th. They issued an “overweight” rating and a $104.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and eighteen have assigned a buy rating to the company’s stock. Spark Therapeutics has a consensus rating of “Buy” and a consensus target price of $90.36.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Belpointe Asset Management LLC bought a new stake in shares of Spark Therapeutics during the 3rd quarter valued at about $403,000. Neuberger Berman Group LLC bought a new stake in shares of Spark Therapeutics during the 3rd quarter valued at about $672,000. Cubist Systematic Strategies LLC boosted its stake in shares of Spark Therapeutics by 257.7% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 8,588 shares of the biotechnology company’s stock valued at $766,000 after purchasing an additional 6,187 shares in the last quarter. Perceptive Advisors LLC bought a new stake in shares of Spark Therapeutics during the 3rd quarter valued at about $16,049,000. Finally, Orbimed Advisors LLC bought a new stake in shares of Spark Therapeutics during the 3rd quarter valued at about $38,340,000. 94.94% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Spark Therapeutics Inc (ONCE) CFO Stephen W. Webster Sells 10,000 Shares” was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this news story on another site, it was stolen and republished in violation of US and international copyright & trademark laws. The correct version of this news story can be viewed at https://ledgergazette.com/2017/12/07/spark-therapeutics-inc-once-cfo-stephen-w-webster-sells-10000-shares.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.